2021
The results from the patients in the fifth dose level show, in line with the previous dose levels, that FG001 was well tolerated. The...
The data from the ongoing dose finding trial suggests that background light intensity might be further reduced if FG001 is administered...
The subscription price and the total number of new shares in the Directed Share Issue will be determined by way of an accelerated bookbuilding...
The results from the patients in the fourth dose level show that FG001 was well tolerated, and the light intensity continues to increase...
18 March, 2021
FluoGuide appoints new Certified Adviser
FluoGuide appoints Svensk Kapitalmarknadsgransking AB (SKMG), as its new Certified Adviser (CA), from 1. April 2021. Västra Hamnen...
Photothermal therapy is an extension of photodynamic therapy, in which a photosensitizer (e.g. FG001) is excited with light of a specific...
17 February, 2021
FluoGuide gets green light to proceed to fourth dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma
Evaluation of the results from the third dose level of FG001, including data from three patients, have been finalized and reported...
9 February, 2021
Minutes from the Annual General Meeting in FluoGuide A/S
The agenda for the general meeting was as follows: Henrik Moltke, CFO was elected chairman of the meeting. The chairman ascertained...
5 February, 2021
FluoGuide announces approval for listing on Nasdaq First North Growth Market Sweden on the 24 February 2021
FluoGuide has applied for and received approval for admission to trading on Nasdaq First North. The first day of trading in the Company’s...